Intrabody construction and expression. II. A synthetic catalytic Fv fragment.

In general, proteins with structural disulfides cannot be expressed in the reducing environment of the cellular cytoplasm. To overcome this folding problem, we have previously engineered stabilizing mutations, predicted from a consensus sequence analysis, into isolated immunoglobulin VL domains. Here we show that such domains can be used as a framework in the construction of a functional heterodimeric Fv fragment, which was expressed solubly, with high yield in the cytoplasm of Escherichia coli. This designed catalytic intrabody, obtained from grafting the combining site of the esterolytic antibody 17E8, is active in the oxidized and the reduced state. Its construction required no special features on the part of the immunoglobulin, no single-chain linker and introduced no non-natural sequence motifs. The potential to design intrabodies with the recognition sequences of arbitrary immunoglobulins opens novel opportunities for gene therapy, cell biology, metabolic engineering and antibody biotechnology.

[1]  P. Wirtz,et al.  Intrabody construction and expression III: Engineering hyperstable VH domains , 2008, Protein science : a publication of the Protein Society.

[2]  E Ohage,et al.  Intrabody construction and expression. I. The critical role of VL domain stability. , 1999, Journal of molecular biology.

[3]  A. Cattaneo,et al.  The selection of intracellular antibodies. , 1998, Trends in biotechnology.

[4]  P. Hudson,et al.  Recombinant antibody fragments. , 1998, Current opinion in biotechnology.

[5]  S. Chen,et al.  Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. , 1998, Human gene therapy.

[6]  P. Martineau,et al.  Expression of an antibody fragment at high levels in the bacterial cytoplasm. , 1998, Journal of molecular biology.

[7]  A. Plückthun,et al.  An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly , 1998, FEBS letters.

[8]  A. Plückthun,et al.  Antibody scFv fragments without disulfide bonds made by molecular evolution. , 1998, Journal of molecular biology.

[9]  A. Cattaneo,et al.  Rescue of a neutralizing anti‐viral antibody fragment from an intracellular polyclonal repertoire expressed in mammalian cells , 1997, FEBS letters.

[10]  S. Benkovic,et al.  The state of antibody catalysis. , 1997, Current opinion in biotechnology.

[11]  P. Carter,et al.  Engineering antibodies for imaging and therapy. , 1997, Current opinion in biotechnology.

[12]  A. Plückthun,et al.  A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. , 1997, Journal of molecular biology.

[13]  S. Steinbacher,et al.  β‐Turn propensities as paradigms for the analysis of structural motifs to engineer protein stability , 1997, Protein science : a publication of the Protein Society.

[14]  O. Bagasra,et al.  Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle , 1996, Journal of Virology.

[15]  A. Cattaneo,et al.  Redox State of Single Chain Fv Fragments Targeted to the Endoplasmic Reticulum, Cytosol and Mitochondria , 1995, Bio/Technology.

[16]  R. Lerner,et al.  From molecular diversity to catalysis: lessons from the immune system. , 1995, Science.

[17]  M. Reitz,et al.  Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro , 1995, Nature Medicine.

[18]  A. Skerra.  Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. , 1994, Gene.

[19]  R J Fletterick,et al.  Crystal structure of a catalytic antibody with a serine protease active site. , 1994, Science.

[20]  S. Steinbacher,et al.  Sequence statistics reliably predict stabilizing mutations in a protein domain. , 1994, Journal of molecular biology.

[21]  T. Scanlan,et al.  KINETIC AND MECHANISTIC CHARACTERIZATION OF AN EFFICIENT HYDROLYTIC ANTIBODY : EVIDENCE FOR THE FORMATION OF AN ACYL INTERMEDIATE , 1994 .

[22]  A. Plückthun,et al.  An Escherichia coli protein consisting of a domain homologous to FK506-binding proteins (FKBP) and a new metal binding motif. , 1994, The Journal of biological chemistry.

[23]  A. Plückthun,et al.  Refined crystal structure of a recombinant immunoglobulin domain and a complementarity-determining region 1-grafted mutant. , 1993, Journal of molecular biology.

[24]  R. Glockshuber,et al.  The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. , 1992, Biochemistry.

[25]  Matthews Cr,et al.  Folding and stability of trp aporepressor from Escherichia coli. , 1990 .

[26]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[27]  D. Baltimore,et al.  Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a γ2a variable region , 1981, Cell.

[28]  A. Plu,et al.  An intrinsically stable antibody scFv fragment can tolerate the loss of both disul¢de bonds and fold correctly , 1998 .

[29]  W. Marasco.  Intrabodies: turning the humoral immune system outside in for intracellular immunization , 1997, Gene Therapy.

[30]  W. Marasco,et al.  Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. , 1997, Annual review of microbiology.

[31]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[32]  M. Gittelman,et al.  Folding and stability of trp aporepressor from Escherichia coli. , 1990, Biochemistry.